Abstract
Drug-induced liver injury (DILI) is one of the primary reasons why a new drug candidate may fail during development. To address this challenge, a mathematical representation, DILIsym®, has been developed as a result of an ongoing public-private partnership involving scientists from industry, academia, and the FDA. DILIsym employs mathematical representations of mechanistic interactions and events from drug administration through the progression of liver injury and regeneration to the release of traditional and novel serum biomarkers. The model parameters are varied to recreate population variation in DILI susceptibility. Using in vitro data to represent potential mitochondrial dysfunction, bile acid transporter inhibition, and/or reactive oxygen species generation, DILIsym has been able to predict the in vivo liver safety profile in individuals and in simulated populations for a growing list of drugs. DILIsym is being increasingly used to assist in decision making throughout the development pipeline, from predicting interspecies differences and their hepatotoxicity potential to aiding in the design of dosing regimens to minimize hepatotoxicity when this liability is identified. Furthermore, DILIsym’s incorporation of the release and clearance kinetics of traditional and emerging serum biomarkers can improve interpretation of potential liver safety signals. This chapter outlines the interactions and toxicity mechanisms included in DILIsym and the process of representing a compound in the software. Examples of toxicity profile predictions and biomarker interpretations are included along with future directions for the software.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Olson H, Betton G, Robinson D et al (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56–67. https://doi.org/10.1006/rtph.2000.1399
Dixit R, Boelsterli UA (2007) Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov Today 12:336–342. https://doi.org/10.1016/j.drudis.2007.02.018
Valerio LG Jr (2009) In silico toxicology for the pharmaceutical sciences. Toxicol Appl Pharmacol 241:356–370. https://doi.org/10.1016/j.taap.2009.08.022
Greer ML, Barber J, Eakins J, Kenna JG (2010) Cell based approaches for evaluation of drug-induced liver injury. Toxicology 268:125–131. https://doi.org/10.1016/j.tox.2009.08.007
Sugiyama Y, Yamashita S (2011) Impact of microdosing clinical study – why necessary and how useful? Adv Drug Deliv Rev 63:494–502. https://doi.org/10.1016/j.addr.2010.09.010
Astashkina A, Mann B, Grainger DW (2012) A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol Ther 134:82–106. https://doi.org/10.1016/j.pharmthera.2012.01.001
LeCluyse EL, Witek RP, Andersen ME, Powers MJ (2012) Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 42:501–548. https://doi.org/10.3109/10408444.2012.682115
Howell BA, Yang Y, Kumar R et al (2012) In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI. J Pharmacokinet Pharmacodyn 39:527–541. https://doi.org/10.1007/s10928-012-9266-0
Woodhead JL, Howell BA, Yang Y et al (2012) An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. J Pharmacol Exp Ther 342:529–540. https://doi.org/10.1124/jpet.112.192930
Howell BA, Siler SQ, Watkins PB (2014) Use of a systems model of drug-induced liver injury (DILIsym(®)) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice. Toxicol Lett 226:163–172. https://doi.org/10.1016/j.toxlet.2014.02.007
Woodhead JL, Yang K, Siler SQ et al (2014) Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury. Front Pharmacol 5:240. https://doi.org/10.3389/fphar.2014.00240
Yang K, Woodhead JL, Watkins PB et al (2014) Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther:589–598. https://doi.org/10.1038/clpt.2014.158
Yang K, Woodhead J, Morgan R, et al (2015) Mechanistic modeling with DILIsym® predicts dose-dependent clincial hepatotoxicity of AMG 009 that involves bile acid (BA) transporter inhibition. J Pharmacokinet Pharmacodyn. Springer, New York, NY
Longo DM, Yang Y, Watkins PB et al (2016) Elucidating differences in the hepatotoxic potential of tolcapone and entacapone with DILIsym(®), a mechanistic model of drug-induced liver injury. CPT Pharmacomet Syst Pharmacol 5:31–39. https://doi.org/10.1002/psp4.12053
Yang K, Battista C, Woodhead JL et al (2017) Systems pharmacology modeling of drug-induced hyperbilirubinemia: differentiating hepatotoxicity and inhibition of enzymes/transporters. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.619
Bhattacharyya D, Pandit S, Mukherjee R et al (2003) Hepatoprotective effect of Himoliv, a polyherbal formulation in rats. Indian J Physiol Pharmacol 47:435–440
Song Z, McClain CJ, Chen T (2004) S-Adenosylmethionine protects against acetaminophen-induced hepatotoxicity in mice. Pharmacology 71:199–208. https://doi.org/10.1159/000078086
Valentovic M, Terneus M, Harmon RC, Carpenter AB (2004) S-Adenosylmethionine (SAMe) attenuates acetaminophen hepatotoxicity in C57BL/6 mice. Toxicol Lett 154:165–174. https://doi.org/10.1016/j.toxlet.2004.07.010
Chen Y-H, Lin F-Y, Liu P-L et al (2009) Antioxidative and hepatoprotective effects of magnolol on acetaminophen-induced liver damage in rats. Arch Pharm Res 32:221–228. https://doi.org/10.1007/s12272-009-1139-8
Patel SJ, Milwid JM, King KR et al (2012) Gap junction inhibition prevents drug-induced liver toxicity and fulminant hepatic failure. Nat Biotechnol 30:179–183. https://doi.org/10.1038/nbt.2089
Nieminen AL, Saylor AK, Herman B, Lemasters JJ (1994) ATP depletion rather than mitochondrial depolarization mediates hepatocyte killing after metabolic inhibition. Am J Phys 267:C67–C74
Yang Y, Nadanaciva S, Will Y et al (2014) MITOsym®: a mechanistic, mathematical model of hepatocellular respiration and bioenergetics. Pharm Res. https://doi.org/10.1007/s11095-014-1591-0
Zahno A, Brecht K, Morand R et al (2011) The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol 81:432–441. https://doi.org/10.1016/j.bcp.2010.11.002
Mullen PJ, Zahno A, Lindinger P et al (2011) Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochim Biophys Acta 1813:2079–2087. https://doi.org/10.1016/j.bbamcr.2011.07.019
Nadanaciva S, Rana P, Beeson GC et al (2012) Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform. J Bioenerg Biomembr 44:421–437. https://doi.org/10.1007/s10863-012-9446-z
Yang K, Guo C, Woodhead JL et al (2016) Sandwich-cultured hepatocytes as a tool to study drug disposition and drug-induced liver injury. J Pharm Sci 105:443–459. https://doi.org/10.1016/j.xphs.2015.11.008
Perez M-J, Briz O (2009) Bile-acid-induced cell injury and protection. World J Gastroenterol 15:1677–1689
Maillette-de-Buy-Wenniger L, Beuers U (2010) Bile salts and cholestasis. Dig Liver Dis 42:409–418. https://doi.org/10.1016/j.dld.2010.03.015
Dawson SE, Stahl S, Paul N et al (2011) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug induced liver injury in man. Drug Metab Dispos Biol Fate Chem. https://doi.org/10.1124/dmd.111.040758
Morgan RE, van Staden CJ, Chen Y et al (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci Off J Soc Toxicol 136:216–241. https://doi.org/10.1093/toxsci/kft176
Pedersen JM, Matsson P, Bergström CAS et al (2013) Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci Off J Soc Toxicol 136:328–343. https://doi.org/10.1093/toxsci/kft197
Meier PJ, Stieger B (2002) Bile salt transporters. Annu Rev Physiol 64:635–661. https://doi.org/10.1146/annurev.physiol.64.082201.100300
Akita H, Suzuki H, Hirohashi T et al (2002) Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res 19:34–41
Rius M, Hummel-Eisenbeiss J, Hofmann AF, Keppler D (2006) Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione. Am J Physiol Gastrointest Liver Physiol 290:G640–G649. https://doi.org/10.1152/ajpgi.00354.2005
Jackson JP, Freeman KM, Friley WW et al (2016) Basolateral efflux transporters: a potentially important pathway for the prevention of cholestatic hepatotoxicity. Appl Vitro Toxicol 2:207–216. https://doi.org/10.1089/aivt.2016.0023
Uppal H, Saini SPS, Moschetta A et al (2007) Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology 45:422–432. https://doi.org/10.1002/hep.21494
Beilke LD, Aleksunes LM, Holland RD et al (2009) Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice. Drug Metab Dispos Biol Fate Chem 37:1035–1045. https://doi.org/10.1124/dmd.108.023317
Jonker JW, Liddle C, Downes M (2012) FXR and PXR: potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol 130:147–158. https://doi.org/10.1016/j.jsbmb.2011.06.012
Woodhead JL, Yang K, Brouwer KLR et al (2014) Mechanistic modeling reveals the critical knowledge gaps in bile acid-mediated DILI. CPT Pharmacomet Syst Pharmacol 3:e123. https://doi.org/10.1038/psp.2014.21
Trottier J, Caron P, Straka RJ, Barbier O (2011) Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrate. Clin Pharmacol Ther 90:279–286. https://doi.org/10.1038/clpt.2011.124
García-Cañaveras JC, Donato MT, Castell JV, Lahoz A (2012) Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J Lipid Res 53:2231–2241. https://doi.org/10.1194/jlr.D028803
Shoda LKM, Battista C, Siler SQ, et al. (2017) Mechanistic modelling of drug-induced liver injury: investigating the role of innate immune responses. Gene Regul Syst Biol. 11: 1177625017696074. http://doi.org/10.1177/1177625017696074
Fiorentino D, Zlotnik A, TR M et al (2016) IL-10 inhibits cytokine production by activated macrophages. J Immunol 197:1539–1546
Smith D, Lackides G, Epstein L (1990) Coordinated induction of autocrine tumor necrosis factor and interleukin 1 in normal human monocytes and the implications for monocyte-mediated cytotoxicity. Cancer Res 50:3146–3153
Shnyra A, Brewington R, Alipio A et al (1998) Reprogramming of lipopolysaccharide-primed macrophages is controlled by a counterbalanced production of IL-10 and IL-12. J Immunol (Baltim, MD, 1950) 160:3729–3736
Bonaldi T, Talamo F, Scaffidi P et al (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22:5551–5560. https://doi.org/10.1093/emboj/cdg516
Chen G, Li J, Ochani M et al (2004) Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukoc Biol 76:994–1001. https://doi.org/10.1189/jlb.0404242
Cui Y, Konig J, Leier I et al (2001) Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 276:9626–9630. https://doi.org/10.1074/jbc.M004968200
Briz O, Serrano M, MacIas R (2003) Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J 905:897–905
Keppler D (2014) The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos 42:561–565. https://doi.org/10.1124/dmd.113.055772
Ritter JK, Chen F, Sheen YY et al (1992) A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 267:3257–3261
Kamisako T, Leier I, Cui Y et al (1999) Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology (Baltim, MD) 30:485–490. https://doi.org/10.1002/hep.510300220
Lee Y-MA, Cui Y, König J et al (2004) Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics 14:213–223
Kazama H, Ricci J-E, Herndon JM et al (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 29:21–32. https://doi.org/10.1016/j.immuni.2008.05.013
Yang R, Zhang S, Cotoia A et al (2012) High mobility group B1 impairs hepatocyte regeneration in acetaminophen hepatotoxicity. BMC Gastroenterol 12:45. https://doi.org/10.1186/1471-230X-12-45
Venereau E, Casalgrandi M, Schiraldi M et al (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209:1519–1528. https://doi.org/10.1084/jem.20120189
Lu B, Nakamura T, Inouye K et al (2012) Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488:670–674. https://doi.org/10.1038/nature11290
Nyström S, Antoine DJ, Lundbäck P et al (2013) TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis. EMBO J 32:86–99. https://doi.org/10.1038/emboj.2012.328
Antoine DJ, Harris HE, Andersson U et al (2014) A systematic nomenclature for the redox states of high mobility group box (HMGB) proteins. Mol Med (Camb, MA) 20:135–137. https://doi.org/10.2119/molmed.2014.00022
Lu B, Antoine DJ, Kwan K et al (2014) JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A 111:3068–3073. https://doi.org/10.1073/pnas.1316925111
Caulín C, Salvesen GS, Oshima RG (1997) Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138:1379–1394
Kramer G, Erdal H, Mertens HJMM et al (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64:1751–1756
Linder S, Olofsson MH, Herrmann R, Ulukaya E (2010) Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. Expert Rev Mol Diagn 10:353–359. https://doi.org/10.1586/erm.10.14
Howell BA, Siler SQ, Shoda LKM et al (2014) A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial. CPT Pharmacomet Syst Pharmacol 3:e98. https://doi.org/10.1038/psp.2013.74
Portmann B, Talbot IC, Day DW et al (1975) Histopathological changes in the liver following a paracetamol overdose: correlation with clinical and biochemical parameters. J Pathol 117:169–181. https://doi.org/10.1002/path.1711170307
Ulloa JL, Stahl S, Yates J et al (2013) Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition. NMR Biomed 26:1258–1270. https://doi.org/10.1002/nbm.2946
Battista C, Yang K, Mettetal JT et al (2016) Mechanistic modeling with DILIsym® predicts species differences in CKA via multiple hepatotoxic mechanisms. J Pharacokinet Pharmacodyn 43:15
Woodhead JL, Watkins PB, Howell BA et al (2017) The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. Drug Metab Pharmacokinet 32:40–45. https://doi.org/10.1016/j.dmpk.2016.11.008
Horn KD, Wax P, Schneider SM et al (1999) Biomarkers of liver regeneration allow early prediction of hepatic recovery after acute necrosis. Am J Clin Pathol 112:351–357
Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration: a guide for clinicians. Can Med Assoc J 172:367–379. https://doi.org/10.1503/cmaj.1040752
Lewis JH (2006) “Hy’s law,’ the “Rezulin Rule,” and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 15:221–229. https://doi.org/10.1002/pds.1209
Ozer J, Ratner M, Shaw M et al (2008) The current state of serum biomarkers of hepatotoxicity. Toxicology 245:194–205. https://doi.org/10.1016/j.tox.2007.11.021
Antoine DJ, Mercer AE, Williams DP, Park BK (2009) Mechanism-based bioanalysis and biomarkers for hepatic chemical stress. Xenobiotica 39:565–577. https://doi.org/10.1080/00498250903046993
Antoine DJ, Williams DP, Kipar A et al (2009) High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci Off J Soc Toxicol 112:521–531. https://doi.org/10.1093/toxsci/kfp235
Harrill AH, Roach J, Fier I et al (2012) The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther 92:214–220. https://doi.org/10.1038/clpt.2012.40
Murayama H, Ikemoto M, Fukuda Y, Nagata A (2008) Superiority of serum type-I arginase and ornithine carbamyltransferase in the detection of toxicant-induced acute hepatic injury in rats. Clin Chim Acta Int J Clin Chem 391:31–35. https://doi.org/10.1016/j.cca.2008.01.023
Wetmore BA, Brees DJ, Singh R et al (2010) Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury. Hepatol Baltim Md 51:2127–2139. https://doi.org/10.1002/hep.23574
Yang X, Greenhaw J, Shi Q et al (2012) Identification of urinary microRNA profiles in rats that may diagnose hepatotoxicity. Toxicol Sci Off J Soc Toxicol 125:335–344. https://doi.org/10.1093/toxsci/kfr321
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Battista, C., Howell, B.A., Siler, S.Q., Watkins, P.B. (2018). An Introduction to DILIsym® Software, a Mechanistic Mathematical Representation of Drug-Induced Liver Injury. In: Chen, M., Will, Y. (eds) Drug-Induced Liver Toxicity. Methods in Pharmacology and Toxicology. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-7677-5_6
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7677-5_6
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-7676-8
Online ISBN: 978-1-4939-7677-5
eBook Packages: Springer Protocols